Printer Friendly

SCHERING-PLOUGH EXECUTIVE PLANS TO REITERATE CONFIDENCE 'CLARITIN' WILL BE CLEARED FOR MARKET

 MADISON, N.J., Feb. 11 /PRNewswire/ -- Later today at a meeting with securities analysts in New York, Schering-Plough Corporation's (NYSE: SGP) Donald R. Conklin, executive vice president and Schering- Plough Pharmaceuticals president, will re-emphasize the company's confidence that its nonsedating antihistamine Claritin' will be cleared for market soon.
 When speaking to the analysts at a health care conference hosted by Merrill Lynch & Co., Conklin plans to review the status of the Claritin' New Drug Application for seasonal allergic rhinitis -- noting that while predicting the timing of approvals by the U.S. Food and Drug Administration (FDA) is inherently difficult, "The company's Claritin' application appears to have progressed sufficiently so that FDA approval should be granted shortly."
 Conklin bases that belief upon no official action by FDA, but rather on discussions held with, and information requested by, the agency.
 He will tell the analysts that Schering-Plough is prepared to market and ship Claritin' after market clearance.
 Schering-Plough is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide.
 -0- 2/11/93
 /CONTACT: Steve Galpin Jr. of Schering-Plough, 201-822-7415/
 (SGP)


CO: Schering-Plough Corporation ST: New Jersey IN: MTC SU:

SH -- NY010 -- 5527 02/11/93 08:46 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 11, 1993
Words:205
Previous Article:BRADLEES ANNOUNCES QUARTERLY DIVIDEND
Next Article:BP AMERICA REACHES $630 MILLION TAX SETTLEMENT WITH STATE OF ALASKA
Topics:


Related Articles
NEW, ONCE-A-DAY, NONSEDATING Rx ANTIHISTAMINE CLEARED FOR MARKETING; CLARITIN HAS FAST ONSET, LONG DURATION OF ACTION AND FEW SIDE EFFECTS
SCHERING-PLOUGH BRIEFS ANALYSTS ON BUSINESS PERFORMANCE, RESEARCH PROGRESS
CLARITIN-D -- NEWEST PRESCRIPTION OPTION FOR SEASONAL ALLERGIC RHINITIS (HAY FEVER) WITH CONGESTION -- RECEIVES U.S. MARKETING CLEARANCE
SCHERING-PLOUGH REPORTS SALES, EARNINGS FOR 1995 SECOND QUARTER, FIRST HALF
SCHERING-PLOUGH RECEIVES FDA MARKETING CLEARANCE FOR CLARITIN(R) FOR URTICARIA (HIVES)
SCHERING-PLOUGH UPDATES ANALYSTS ON 1995 BUSINESS PERFORMANCE
Schering-Plough Reports Sales, Earnings For First Quarter of 1997
Schering-Plough Reviews Research and Business Progress, Sharpens 1997 Earnings Projection
Schering-Plough Reports Sales, Earnings For 1997 Second Quarter, First Half
Claritin(R) Renews Sponsorship With Allergy Sufferer and NASCAR Star Carl Edwards.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters